Market Overview

Cowen Analyst Thinks Shire-Radius Health Merger Is Unlikely After Visit With CEO

Share:
Cowen Analyst Thinks Shire-Radius Health Merger Is Unlikely After Visit With CEO
Related RDUS
14 Stocks Moving In Tuesday's Pre-Market Session
15 Stocks Moving In Monday's Pre-Market Session
Related
Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
18 Biggest Mid-Day Losers For Tuesday
  • Shares of Radius Health Inc (NASDAQ: RDUS) spiked 20.72 percent on massive volume (3.8 million shares, versus the 1.1 million average) on Thursday.
  • The surge seemed to have been triggered by rumors about a possible takeover by Shire PLC (ADR) (NASDAQ: SHPG).
  • Shares of Shire rose 2.77 percent during the regular trading session, but fell almost 2 percent in after-hours Thursday.

Radius Health’s stock spiked on Thursday following rumors that say Shire intends to make a takeover offer of $90 per share for the company. It should be noted that this is a huge premium to Radius’ stock’s current valuation -- shares opened at $54.15 on Thursday.

So far, both Radius and Shire have declined to comment.

To shed some light on the subject, Benzinga contacted research firm Cowen & Co.

A prominent analyst at the firm, Dr. Eric Schmidt, revealed the following in a phone interview:

1. The Shire-Radius rumor seems unlikely. Shire has been subject of plenty of speculation regarding its M&A activity recently.

2. Radius Health’s President and CEO visited Cowen’s office on Thursday afternoon and did not say anything about the potential acquisition.

Radius stock does not yet appear to be reacting to the possibility that the latest rumor is false. Shares breached the $66 level in Thursday's afte-hours session after bottoming at $46.32 just one day earlier.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Image credit: Public Domain

Latest Ratings for RDUS

DateFirmActionFromTo
May 2016H.C. WainwrightInitiates Coverage onBuy
May 2016Cowen & Co.AssumesOutperform
Mar 2016Goldman SachsInitiates Coverage onNeutral

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Short Ideas Health Care M&A Top Stories Exclusives Analyst Ratings Best of Benzinga

 

Related Articles (SHPG + RDUS)

View Comments and Join the Discussion!